File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer

TitleCoexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer
Authors
KeywordsDuctal carcinoma in situ (DCIS)
Invasive ductal carcinoma (IDC)
Ki67
Luminal breast cancer
Issue Date2012
PublisherHumana Press, Inc. The Journal's web site is located at http://www.humanapress.com/JournalDetail.pasp?journal=14
Citation
Medical Oncology, 2012, v. 29 n. 3, p. 1536-1542 How to Cite?
AbstractPrimary breast invasive ductal carcinoma coexisting with ductal carcinoma in situ (IDC-DCIS) is characterized by lower proliferation rate and metastatic propensity than size-matched pure IDC. IDC-DCIS is also more often ER-positive, PR-positive and/or HER2-positive. This analysis aims to clarify whether the presence of coexisting DCIS in IDC affects tumor aggressiveness in various biological subtypes of breast cancer, respectively. Tumor data obtained from 1,355 consecutive female patients undergoing upfront surgery for primary breast cancer were analyzed retrospectively; 196 patients with pure DCIS were excluded. Based on evidence that immunohistochemistry (IHC) provides a reasonable approximation of molecular phenotypes, the tumor samples were divided into 4 groups: (1) luminal A (ER and/or PR-positive, HER2-negative, Ki67 ≤ 12), (2) luminal B (ER and/or PR-positive, HER2-negative, Ki67 > 12), (3) HER2 (HER2-positive) and (4) basal-like (triple-negative) disease. Ki67 expression and nodal involvement of IDC with or without DCIS in these groups were compared. The number of patients with luminal A, luminal B, HER2 and basal-like breast cancer were 396, 265, 258 and 117, respectively. Ki-67 was lower in IDC-DCIS than in size-adjusted pure IDC of both luminal A and luminal B subtypes (P = 0.15 and <0.005, respectively). In HER2 or basal-like tumors, there were no significant difference between pure IDC and IDC-DCIS. The presence of coexisting DCIS in IDC predicts lower biological aggressiveness in luminal cancers but not in the conventionally more aggressive HER2-positive and triple-negative subtypes. © 2011 Springer Science+Business Media, LLC.
Persistent Identifierhttp://hdl.handle.net/10722/159621
ISSN
2015 Impact Factor: 2.486
2015 SCImago Journal Rankings: 0.837
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, Hen_HK
dc.contributor.authorLau, Sen_HK
dc.contributor.authorLeung, Ren_HK
dc.contributor.authorChiu, Jen_HK
dc.contributor.authorCheung, Pen_HK
dc.contributor.authorWong, TTen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorEpstein, RJen_HK
dc.contributor.authorYau, Ten_HK
dc.date.accessioned2012-08-16T05:53:28Z-
dc.date.available2012-08-16T05:53:28Z-
dc.date.issued2012en_HK
dc.identifier.citationMedical Oncology, 2012, v. 29 n. 3, p. 1536-1542en_HK
dc.identifier.issn1357-0560en_HK
dc.identifier.urihttp://hdl.handle.net/10722/159621-
dc.description.abstractPrimary breast invasive ductal carcinoma coexisting with ductal carcinoma in situ (IDC-DCIS) is characterized by lower proliferation rate and metastatic propensity than size-matched pure IDC. IDC-DCIS is also more often ER-positive, PR-positive and/or HER2-positive. This analysis aims to clarify whether the presence of coexisting DCIS in IDC affects tumor aggressiveness in various biological subtypes of breast cancer, respectively. Tumor data obtained from 1,355 consecutive female patients undergoing upfront surgery for primary breast cancer were analyzed retrospectively; 196 patients with pure DCIS were excluded. Based on evidence that immunohistochemistry (IHC) provides a reasonable approximation of molecular phenotypes, the tumor samples were divided into 4 groups: (1) luminal A (ER and/or PR-positive, HER2-negative, Ki67 ≤ 12), (2) luminal B (ER and/or PR-positive, HER2-negative, Ki67 > 12), (3) HER2 (HER2-positive) and (4) basal-like (triple-negative) disease. Ki67 expression and nodal involvement of IDC with or without DCIS in these groups were compared. The number of patients with luminal A, luminal B, HER2 and basal-like breast cancer were 396, 265, 258 and 117, respectively. Ki-67 was lower in IDC-DCIS than in size-adjusted pure IDC of both luminal A and luminal B subtypes (P = 0.15 and <0.005, respectively). In HER2 or basal-like tumors, there were no significant difference between pure IDC and IDC-DCIS. The presence of coexisting DCIS in IDC predicts lower biological aggressiveness in luminal cancers but not in the conventionally more aggressive HER2-positive and triple-negative subtypes. © 2011 Springer Science+Business Media, LLC.en_HK
dc.languageengen_US
dc.publisherHumana Press, Inc. The Journal's web site is located at http://www.humanapress.com/JournalDetail.pasp?journal=14en_HK
dc.relation.ispartofMedical Oncologyen_HK
dc.subjectDuctal carcinoma in situ (DCIS)en_HK
dc.subjectInvasive ductal carcinoma (IDC)en_HK
dc.subjectKi67en_HK
dc.subjectLuminal breast canceren_HK
dc.titleCoexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast canceren_HK
dc.typeArticleen_HK
dc.identifier.emailEpstein, RJ: repstein@hku.hken_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.authorityEpstein, RJ=rp00501en_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12032-011-0082-yen_HK
dc.identifier.pmid21983862-
dc.identifier.scopuseid_2-s2.0-84872781546en_HK
dc.identifier.hkuros202626en_US
dc.identifier.volumeEpub on 2011-10-08en_US
dc.identifier.spage1536en_HK
dc.identifier.epage1542en_HK
dc.identifier.isiWOS:000307964100021-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, H=23089414000en_HK
dc.identifier.scopusauthoridLau, S=36118928300en_HK
dc.identifier.scopusauthoridLeung, R=52364352500en_HK
dc.identifier.scopusauthoridChiu, J=36887309300en_HK
dc.identifier.scopusauthoridCheung, P=7202595368en_HK
dc.identifier.scopusauthoridWong, TT=26323418500en_HK
dc.identifier.scopusauthoridLiang, R=52364453400en_HK
dc.identifier.scopusauthoridEpstein, RJ=34975074500en_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.citeulike9896315-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats